New Gene-Targeting drug could change how we treat high blood pressure

NCT ID NCT06205628

Ongoing Disease control Sponsor: ADARx Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times

Summary

This early-stage study tests a new drug called ADX-850 in 28 people with mild to moderate high blood pressure. The drug uses siRNA technology to target genes involved in blood pressure regulation. The main goal is to check safety and how the drug moves through the body, with a secondary look at its effect on blood pressure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ADX-850 (siRNA drug)
What this could lead to: If successful, this could lead to a new treatment option for high blood pressure that may require less frequent dosing.
What could go wrong: This is an early Phase 1 study with only 28 participants, so safety and effectiveness are not yet proven. The drug may not lower blood pressure enough or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension essential hypertension, genetic hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION HYPERTENSION,ESSENTIAL

Contacts and locations

Locations

CMAX Clinical Research

Adelaide, South Australia, 5000, Australia
Clinitrials Pty Ltd

Perth, Australia
Linear Clinical Research

Nedlands, Western Australia, 6009, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.